Skin-focused Sirona Biochem is liquidating its R&D subsidiary after a pair of financing deals and a licensing agreement with ...

A new Caribbean company has emerged to enter the increasingly crowded T-cell engager space. | A new Caribbean company has ...

Baxter saw its stock price plunge by more than 20% after it lowered its revenue projections for the remainder of this year, ...

Allogene Therapeutics has reported a patient death tied to its anti-CD52 monoclonal antibody used for lymphodepletion in its ...

Despite the recent buzz, the effort to reduce animal testing in favor of NAMs has been underway for years. The VQN falls ...

Sanofi is handing over $130 million upfront for the China rights to Arrowhead Pharmaceuticals’ rare metabolic disease ...

AbbVie is ending development of an IL-1 asset as a monotherapy in ulcerative colitis (UC) after a phase 2 study revealed ...

A PD-L1xVEGF bispecific antibody from China’s ImmuneOnco Biopharmaceuticals has shown early promise in shrinking lung tumors, ...

AbbVie has reportedly added Gilgamesh Pharmaceuticals to its shopping list. | AbbVie has reportedly added Gilgamesh ...

Last week, Australian life sciences venture capital firm Brandon Capital closed its largest fund yet, raising A$439 million ...

A phase 3 trial of Spine BioPharma’s chronic low back pain candidate has missed its primary endpoint. But, with the biotech pinning the failure on a “very high sham control response,” management plans ...

Barcelona-based InBrain Neuroelectronics shared interim findings from a first-in-human clinical study of its graphene-based ...